SFSamantha Roman Fox

Samantha Roman Fox

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samantha Roman Fox has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring if Longitudinal Changes on PET Imaging Can Serve as a Biomarker for Stiff Person Syndrome Spectrum Disorders

    by Munther M. Queisi, Samantha N. Roman, Mohammad S. Sadaghiani, Lilja B. Solnes, Scott D. Newsome

    Objective: To identify metabolic patterns in the brain and musculoskeletal system of stiff person syndrome spectrum disorders (SPSD) patients over time using PET imaging and evaluate the impact of immune therapy on metabolic activity as a surrogate for treatment response. Methods: This observational study at the Johns Hopkins SPS Center of Excellence included adults (≥ 18 years) diagnosed with classic SPS, partial SPS, SPS plus, or PERM, who were treated from 2009 to 2023. Participants underwent at least two whole‐body and/or dedicated brain PET scans. Brain PET analysis utilized NeuroQ v3.8 software to generate standardized Z ‐scores for 47 distinct brain regions, assessed by expert nuclear medicine radiologists. Patient demographics, antibody types, immune therapies, and symptomatic treatments were assessed. Results: Eighteen patients met inclusion criteria (10 SPS plus, 6 classic SPS, 2 PERM), with a mean age of 50.7 (SD 8.5) years; 77.8% were female and 50.0% were Black/African American. Hypermetabolic activity and hypometabolism were both seen over time in the brain and the musculoskeletal system. Two patients starting immune therapy in between PET scans demonstrated improvement in brain but not body PET findings. Interpretation: The study findings indicate that PET imaging abnormalities are present over time and appear to have regional patterns that are common among phenotypes. Additionally, starting immune therapy between scans appears to correlate with stabilization or improvement in brain PET abnormalities, though this was less clear in body PET scans. PET scans have the potential to be an imaging biomarker in SPSD, but future studies are needed to validate this.


  • Open Access

    Botulinum toxin as a potential adjunct therapy in stiff person syndrome spectrum disorders

    by Samantha N. Roman, Jacqueline L. Koshorek, Elena R. Taylor, Herbert R. Chen, Scott D. Newsome, Emile S. Moukheiber

    Background: Stiff person syndrome spectrum disorders (SPSD) are a disabling group of immune-mediated disorders that most commonly cause progressive rigidity and painful spasms. Botulinum neurotoxin (BoNT) has anecdotally improved SPSD symptoms, though evidence regarding treatment strategy and clinical efficacy is scarce. Objectives: To characterize the location, frequency, dosage, and clinical response to BoNT injections in patients with SPSD. Design: We conducted a retrospective observational cohort study. Methods: SPSD patients who received BoNT treatments between August 2018 and February 2024 were included. Detailed information about the injections (formulation, dose, muscle), subjective patient-reported response, and concurrent therapies was recorded and compared between the first, third, and eighth BoNT visits. Results: Thirty-seven SPSD patients were included. The majority had classic SPS (83.8%), were female (67.7%), white (78.4%), and on immune therapies (70.3%). The paraspinal muscles, hip flexors, distal leg flexors, and shoulder girdle muscles were most frequently injected. Supramaximal total doses up to 980 units of BoNT were used safely. The most common side effect was transient worsening of pain/spasms, which resolved with peak dose effect. Subjective clinical response was positive, with a median patient-reported 5-point Likert rating of 4, 5, and 5 after visits 1, 3, and 8. Conclusion: BoNT may be an effective and durable adjunctive symptomatic therapy for people with SPSD with targeted muscle selection based on specific symptomatology. Injections into multiple body regions and use of supramaximal dosages may be required for adequate symptom control in this patient population. As our data lacked objective measures and relied on semiqualitative self-reported patient responses, conclusions about the utility of BoNT are limited and randomized placebo-controlled trials are needed to evaluate the impact of BoNT on improving quality of life, mobility, and burden of systemic symptomatic treatment.


  • Open Access

    Quantitative brain 18F‐FDG PET/CT analysis in seronegative autoimmune encephalitis

    by Samantha N. Roman, Moe S. Sadaghiani, Luisa A. Diaz‐Arias, Marion Le Marechal, Arun Venkatesan, Lilja B. Solnes, John C. Probasco

    Objective: Brain Brain F-18-FDG PET/CT is a useful diagnostic in evaluating patients with suspected autoimmune encephalitis (AE). Specific patterns of brain dysmetabolism have been reported in anti-NMDAR and anti-LGI1 AE, and the degree of dysmetabolism may correlate with clinical functional status.(18)FDG-PET/CT abnormalities have not yet been described in seronegative AE. Methods: We conducted a cross-sectional analysis of brain(18)FDG-PET/CT data in people with seronegative AE treated at the Johns Hopkins Hospital. Utilizing NeuroQ (TM) software, the Z-scores of 47 brain regions were calculated relative to healthy controls, then visually and statistically compared for probable and possible AE per clinical consensus diagnostic criteria to previous data from anti-NMDAR and anti-LGI1 cohorts. Results: Eight probable seronegative AE and nine possible seronegative AE were identified. The group only differed in frequency of abnormal brain MRI, which was seen in all of the probable seronegative AE patients. Both seronegative groups had similar overall patterns of brain dysmetabolism. A common pattern of frontal lobe hypometabolism and medial temporal lobe hypermetabolism was observed in patients with probable and possible seronegative AE, as well as anti-NMDAR and anti-LGI1 AE as part of their respective characteristic patterns of dysmetabolism. Four patients had multiple brain(18)FDG-PET/CT scans, with changes in number and severity of abnormal brain regions mirroring clinical status. Conclusions: A(18)FDG-PET/CT pattern of frontal lobe hypometabolism and medial temporal lobe hypermetabolism could represent a common potential biomarker of AE, which along with additional clinical data may facilitate earlier diagnosis and treatment.


  • Open Access

    The impact of medical students on work after clinic for neurology preceptors

    by Andrew G. Breithaupt, Samantha N. Roman, William H. Coe, Rachel E. Salas, Roy E. Strowd, Jeremy A. Tanner, Karthik T. Rao, Charlene E. Gamaldo

  • The prevalence and utility of screening for urinary tract infection at the time of presumed multiple sclerosis relapse

    by Kathryn C. Fitzgerald, Lydia A. Cassard, Samantha Roman Fox, John C. Probasco, Sandra D. Cassard, Ellen M. Mowry